One of the largest patient populations for off-label antidote use is children, a demographic group not usually addressed in the original FDA approval. Off-label drug use ranges 20-30% for inpatients and as a high as 60% in newborns [5, 6] . Like most drugs, many antidotes are not specifically approved for pediatric use, usually due to a lack of age specific safety, dosing, and efficacy studies. Many drugs approved in adults can cause untoward effects in children: promethazine (respiratory arrest), tetracylcines (dental staining), chloramphenicol (gray baby syndrome) and propofol (infusion deaths). In its infinite wisdom, the FDA initially addressed this problem with Pediatric Rule 1994 that allowed establishment of pediatric indications based on extrapolation of adult data [7] . Subsequently, in 1997 the FDA arranged for extended marketing rights through the Food and Drug Administration Modernization Act [8] . This act provided 6 months of exclusive marketing to drug manufacturers if they submit convincing pediatric clinical trial data. Since that time, almost 120 drugs have been granted pediatric exclusivity [9] . Unfortunately, none of them are antidotes.
One would think that the use of an off-label drug would be a defiant act, flaunting FDA directives. However, even the U.S. Supreme Court has ruled that the "off-label usage of medical devices is an accepted and necessary corollary of the FDA's mission to regulate" [10] . They go on to state that health care practitioners can "prescribe or administer any legally marketed device to a patient" without limitation or interference. The Center for Drug Evaluation and Research confirms this stance, stating that "neither the FDA nor the Federal government regulate the practice of medicine," and "any approved product may be used by a licensed practitioner for uses other that those stated in the product label" [11] . In addition, physicians may discuss such uses in print or lecture without censure. As of 2004, the Accreditation Council for Continuing Medical Education has dropped requirements for disclosure when mentioning use of off-label drugs or products in CME activities [12] . When asked about the extent of the FDA's ability to regulate speech concerning off-label uses, the FDA responded on-line with "Get your hands OFF the docs!" [13] In advancing scientific medicine through off-label prescribing, physicians may even redefine what is considered appropriate treatment. In a case involving off-label use of terbutaline for premature labor, in spite of a bad outcome, the courts stated that the "off-label use of a [ . . . ] drug or device may even define the standard of care" [14] . Such use is not research or experimentation. If the primary intent of the clinician is to benefit the patient, rather than publish, then no Institutional Review Board or Investigational Drug Application is required [15] . The FDA recognizes that "off-label use is a well-established principle that has allowed doctors to discover new and beneficial uses" for previously approved drugs [14] .
In multiple instances, courts have stated that the use of an offlabel drug does not in itself constitute malpractice. In the case of the myocardial infarction induced by off-label terbutaline for tocolysis, a state appellate court ruled that the off-label nature of the drug was immaterial to the case [14] . Likewise, the Minnesota Court of Appeals in 1997 stated that physicians did not have to disclose the off-label nature of their therapy [16] . The case involved screws approved by the FDA for long bone fractures, which were used off-label by orthopedists in spinal surgery. Plaintiffs, having sustained damages, charged physicians for negligence in failing to disclose and obtain consent for off-label therapy. The court ruled in the physicians' favor, concluding that off-label use in itself does not imply that a therapy is "unsafe, risky, novel, or untried." Physicians may safely prescribe any drug off-label provided they practice a standard of care based on sound evidence.
In the end, the FDA, the courts, and logic support that toxicologists may use any approved product or medication in any manner deemed clinically appropriate. And as a journal presenting cutting edge information, the Journal Medical Toxicology has an obligation to publish responsible peer-reviewed studies and case reports exploring off-label uses of FDA approved drugs. In toxicology, off-label use of a drug more often than not defines the standard of care. Toxicologists work independently of government scrutiny, using collective scientific exchange to advance our specialty responsibly. We, rest assured, can treat our patients well without infringements on our ability to practice quality, cutting edge medical care.
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